Latest News for LTRN
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN) (“Lantern” or the “Company”), an AI-driven clinical-stage precision oncology company, today announced that withZeta.ai — the world's first and most comprehensive multi-agentic AI co-scientist for rare cancer drug discovery, development, biomedical research, molecular design and clinical trial development — is now commercially live and actively onboarding…
Lantern Pharma Inc. (LTRN) Shareholder/Analyst Call Transcript
DALLAS--(BUSINESS WIRE)--withZeta.ai is redefining how rare cancer research, discovery, drug development, and clinical trial design gets done.
Lantern Pharma Inc. (LTRN) Q4 2025 Earnings Call Prepared Remarks Transcript
DALLAS--(BUSINESS WIRE)--Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LTRN.
U.S. House Trading
No House trades found for LTRN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.